Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of PT2977 in Combination With Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT03634540 is registered in ClinicalTrials.gov with Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) as lead sponsor.

NCT NCT03634540
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03634540 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of PT2977 in Combination With Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Lead sponsor
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 27, 2018
Completion date
February 26, 2027
Enrollment
118 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma (ccrcc), kidney, kidney cancer, renal cancer, renal cell cancer metastatic, renal cell cancer, recurrent, renal cell carcinoma, renal cell carcinoma (rcc), renal cell carcinoma recurrent